Weiwei
Wang
a,
Chen
Li
a,
Ju
Zhang
a,
Anjie
Dong
b and
Deling
Kong
*a
aTianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, 300192, China. E-mail: kongdeling@nankai.edu.cn
bSchool of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, China
First published on 10th February 2015
Correction for ‘Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy’ by Weiwei Wang et al., J. Mater. Chem. B, 2014, 2, 1891–1901.
The in vivo drug concentration dose is incorrectly stated as 26 mg kg−1 throughout the manuscript (Abstract, sentence 8; section 2.8, paragraph 2, sentence 5; section 3.6, sentence 2; Discussion, paragraph 7, sentence 9). The correct dose administered was 0.693 mg mL−1 obtained by concentrating the nanoparticle suspensions and the injection volume was 250 μL.
In several instances (section 3.1, paragraph 2, sentence 8; section 3.2, sentence 5; Table 1, column 7) the drug loading should be 30.4% and 17.7% for PMMA5 and PMMA11.2, rather than 43.7% and 21.5%, respectively. The drug loading in the manuscript had been calculated using the formula Gem/PMMA, rather than by the more accurate formula Gem/(Gem + PMMA).
The conclusions remain unchanged.
References
1 D. Trung Bui, A. Maksimenko, D. Desmaële, S. Harrisson, C. Vauthier, P. Couvreur and J. Nicolas, Biomacromolecules, 2013, 14, 2837–2847.
2 S. Harrisson, J. Nicolas, A. Maksimenko, D. T. Bui, J. Mougin and P. Couvreur, Angew. Chem., Int. Ed., 2013, 52, 1678–1682.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2015 |